Código QR

Japanese rapid/living recommendations on drug management for COVID‐19: updated guidelines (July 2022)

Background Coronavirus disease (COVID‐19), an infectious disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Manageme...

Descrición completa

Gardado en:
Principais autores: Kazuma Yamakawa, Ryo Yamamoto, Takero Terayama, Hideki Hashimoto, Tadashi Ishihara, Go Ishimaru, Haruki Imura, Hiromu Okano, Chihiro Narita, Takuya Mayumi, Hideto Yasuda, Kohei Yamada, Hiroyuki Yamada, Tatsuya Kawasaki, Nobuaki Shime, Kent Doi, Moritoki Egi, Hiroshi Ogura, Morio Aihara, Shigeki Kushimoto, Osamu Nishida, Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J‐SSCG 2020), the COVID‐19 Task Force
Formato: Artigo
Idioma:Inglês
Publicado: Wiley 2022-01-01
Series:Acute Medicine & Surgery
Assuntos:
Coronavirus
GRADE approach
MAGICapp
practice guideline
SARS‐CoV‐2
Acceso en liña:https://doi.org/10.1002/ams2.789
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares